Servier’s $1.55 Billion Muscular Dystrophy Drug Fails Key Trial

The French pharma Servier announced that its experimental drug, sevasemten, has failed to demonstrate efficacy in slowing a rare form of muscular dystrophy during a long placebo-controlled trial. This drug was acquired in June for $1.55 billion in cash, with an additional potential $1 billion in milestones. The results from the pivotal GRAND CANYON study were unexpected, especially since earlier smaller studies had shown promising outcomes. Servier stated that it is conducting a thorough analysis of the GRAND CANYON study dataset alongside relevant prior clinical data to better understand the findings.

This setback is significant not only for Servier but also for patients suffering from Becker muscular dystrophy, who currently lack approved treatment options. The failure of sevasemten may impact Servier’s future investment strategies and could lead to increased scrutiny of its clinical development processes.

Source: statnews.com · Image: New Orleans Pharmacy Museum – 15 by Jeremy Thompson, CC BY 2.0, via Wikimedia Commons